Masterclass: The Legacy of Pear Therapeutics

Despite ambitious goals, innovative in-pipeline and on-market products, Pear Therapeutics faced go-to-market challenges and revenue difficulties. 

High R&D expenses and excessive spending on keeping its operation afloat showed dedication, but could not be sufficiently recouped through revenue. Adoption barriers, like patient awareness and physician hesitancy, revealed complexities in integrating this technology into healthcare. 

Nearly one year following Pear’s bankruptcy, the company’s assets were acquired by four companies, Click Therapeutics, Harvest BIO, Nox Health Group, and Welt. While certainly a testimony to Pear’s scientific work, we’d like to know what this means for digital therapeutics in general. Join your peers to discuss the industry implications of Pear’s legacy.         

Join this meeting to explore: 

• What are the broader implications of Pear’s experience for the future of the digital health industry? 
• Does confidence in this technology hold strong? What does future market shaping look like?  
• Learning from Pear’s failures, how can we drive revenue generation with an innovative product line?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.